Looking to keep its edge in metabolic health, Novo Nordisk A/S is turning to an agreement signed with Flagship Pioneering and its Pioneering Medicines unit to tap into early stage science, specifically in obesity and non-alcoholic steatohepatitis (NASH), through a pair of research collaborations unveiled on 4 January with Omega Therapeutics, Inc. and Cellarity.
Novo Nordisk Calls On Two Flagship Firms For Early Science In Metabolic Health
Derived from a 2022 collaboration between the two, Novo Nordisk will partner with Flagship-backed Omega in obesity and Cellarity in NASH. Both programs are in very early stages at present.
More from Deals
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Business
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.